<aside> 💡

The Big Pivot: Faeve’s 2024 Turning Point

Faeve began in 2017 as a passion project—an opportunity to help people and experiment with plant-based science, all while I maintained my primary focus on running two medical practices. Initially, I had no formal business plan or industry roadmap; I simply enjoyed formulating products and connecting with customers. As the business gained traction, I immersed myself in botanical research and collaborated with chemists, which rapidly accelerated our growth.

However, as demand increased, I faced new challenges: manufacturing at scale, navigating complex federal regulations, and ensuring product shelf stability. To address these, I transitioned production to a mid-scale model and brought in brokers to help expand distribution. This scaling process revealed additional regulatory hurdles, ultimately pushing us into the over-the-counter (OTC) product space, which brought its own compliance requirements.

To support this critical transition, I invested over $100,000 of my personal funds through Faeve, LLC, along with $22,000 from my son. Despite this commitment, I reached a point where further progress was constrained by the need for additional funding—specifically, to complete final stability testing required for OTC compliance. At present, I am unable to sell certain products until these regulatory steps are finalized, yet I am at the threshold of a major breakthrough.

This journey through the “Big Pivot” has brought Faeve further than most in this industry. Now, with the final regulatory hurdle in sight, I am seeking investment to take Faeve to the next stage. I am fully committed and ready to capitalize on this momentum—this is the opportunity you are investing in.

</aside>